ARTICLE / CLIENT ALERT
Preparing for the End of the COVID-19 Emergency: Deadline Tolling
May 16, 2023
Read time: 5 min
Our April 3, 2023, webinar explored the impacts that the end of the PHE and NE will have on employee benefit plans and what actions employers and benefit plan sponsors should be taking to prepare. Watch the webinar recording “How Employers Should Prepare for the End of the Covid-19 National and Public Health Emergencies” to learn more.
The Biden administration previously announced its intent to end the COVID-19 National Emergency (NE) and the COVID-19 Public Health Emergency (PHE) on May 11, 2023 (read our series introduction for more information). On April 10, 2023, President Biden signed a resolution moving up the end of the NE to April 10, 2023 (the PHE ended on May 11). The US Departments of Labor (DOL), Health and Human Services, and the Treasury (the Departments) issued a set of FAQs on March 29, 2023 (FAQs), which anticipated that the NE would end on May 11, 2023 (see our prior article explaining the FAQs). Plan sponsors should continue to treat May 11 as the end of the NE consistent with the FAQs until the Departments say otherwise.
During the COVID-19 pandemic, the Departments provided relief from certain benefit plan deadlines, including:
- The minimum 60-day election period for the Consolidated Omnibus Budget Reconciliation Act (COBRA) continuation coverage.
- The date for making COBRA premium payments (45 days for the initial, then minimum 30-day grace periods).
- The date for individuals to notify the plan of certain qualifying events (divorce, dependent child aging out of plan coverage) or determination of disability as it relates to COBRA coverage.
- The date for providing a COBRA election notice (typically within 14 days after the plan receives notice of a qualifying event).
- The 30-day period (or 60-day period, if applicable) to request Health Insurance Portability and Accountability Act (HIPAA) special enrollment.
- The date within which individuals may file a benefit claim or an appeal of an adverse benefit determination under a plan’s claims procedures.
- The date within which claimants may file a request for an external review after receipt of an adverse benefit determination or final internal adverse benefit determination.
This article discusses how the affected tolled deadlines will be phased out and what actions employers may need to take.
BACKGROUND
EBSA Disaster Relief Notice 2020-01, later extended by EBSA Disaster Relief Notice 2021-01, provided that the deadline by which action needs to be taken for the events described above was tolled until the earlier of: (i) one year from the date the deadline would have first started running for that individual or (ii) sixty (60) days from the end of the NE (the Outbreak Period). This guidance created a tolling deadline specific to each affected individual. Where the individual has not reached the one-year anniversary of the date of the initial deadline, timeframes will begin to run again sixty (60) days after the end of the NE (i.e., July 10, 2023).
The FAQs released by the Departments at the end of March provided much-needed clarification and various helpful examples for employers of how the outbreak period should be taken into consideration when calculating the tolled deadlines. For example, if an employee experiences a qualifying event under COBRA and loses coverage on April 1, 2023, the deadline for the individual to make a COBRA election is tolled until the earlier of one year from the date they were first eligible to elect COBRA or 60 days following the end of the Outbreak Period. Assuming the NE ends on May 11, 2023, the deadline to make an election is now September 8, 2023 (i.e., 60 days following July 10, 2023). The deadline for a participant to request special enrollment in a group health plan due to the birth or adoption of a child, marriage, loss of health coverage or eligibility for state premium assistance subsidy will begin to run again 60 days after the end of the NE—which will presumably end July 10, 2023. Employees will have a 30-day period (or 60-day period, if applicable) from that date to request HIPAA special enrollment. The deadlines by which participants must file a claim for benefits and appeal an adverse benefit determination were also affected by this tolling, as were the deadlines for the federal or state external review process, which will also begin to run 60 days after the end of the NE.
ACTION ITEMS
The DOL has indicated that plan fiduciaries should make reasonable accommodations to prevent the loss of or undue delay of benefit payments. Plan sponsors should also take action to mitigate the possibility of individuals losing out on benefits because of their failure to comply with the affected timeframes. Plan sponsors might consider extending any upcoming deadlines to mitigate the impact on participants and beneficiaries during this transition. Plan administrators and fiduciaries are strongly encouraged to send notices to participants regarding their individual upcoming election and payment deadlines, as well as general changes to plan operations as a result of the end of the NE and PHE. Plan sponsors should consider reissuing prior disclosures made to participants about extension deadlines.
In general, plan sponsors need to revisit their plan documents, summary plan descriptions, notices, and policies and procedures to remove any outdated language related to the tolling of deadlines. After the Outbreak Period, health plans will revert to pre-COVID deadlines.
For any questions regarding the end of the PHE and/or NE, please contact your regular McDermott lawyer or one of the authors.

FDA Issues Draft Guidance on Decentralized Clinical Trials for Drugs, Biological Products and Devices
ARTICLE / CLIENT ALERT
FDA Issues Draft Guidance on Decentralized Clinical Trials for Drugs, Biological Products and Devices
May 15, 2023
Read time: 15 min
Over the past few years, the life sciences and healthcare industries have experienced a notable increase in focus and interest in decentralized clinical trials (DCTs), in which some or all of the trial-related activities occur at locations other than traditional in-person clinical trial sites, along with the technologies and other offerings that typically support them. Because DCTs enable subjects to participate at locations and through methods that may be more convenient for them, DCTs have the potential to expand access to more diverse subject populations that have historically been under-represented in study data and to improve trial efficiencies. In addition, by permitting study activities to occur in different types of clinical settings (for example, a rural hospital versus an academic medical center), sponsors of DCTs and other stakeholders can generate enriched study data that supports a better understanding of the impact of social determinants of health, provider type, training and expertise, setting acuity, and other factors on outcome measures. Building on recommendations to facilitate trial decentralization issued at the beginning of the COVID-19 public health emergency, the US Food and Drug Administrations (FDA) issued guidance on May 2, 2023, that provides recommendations for sponsors, investigators and other stakeholders regarding the implementation of DCTs for drugs, biological products and devices.
As we previously discussed in FDA Offers Guidance on Clinical Trials During Covid-19 Pandemic, FDA issued guidance on March 19, 2020, to provide greater flexibility to adjust clinical protocols and to use telemedicine platforms and virtual clinical sites to address challenges presented by the COVID-19 public health emergency when in-person visits were limited, unsafe or otherwise unavailable for many trial participants.
On May 2, 2023, FDA issued draft guidance, Decentralized Clinical Trials for Drugs, Biological Products, and Devices: Guidance for Industry, Investigators, and Other Stakeholders (Draft Guidance), to assist industry in more broadly adopting DCTs and to meet FDA’s obligations under Section 3606(a) of the Food and Drug Omnibus Reform Act (FDORA), which required FDA to issue or revise draft guidance to advance the use of DCTs to support drug and device development on or before December 29, 2023. The Draft Guidance should be considered along with FDA’s December 2021 draft Digital Health Technologies for Remote Data Acquisition in Clinical Investigations guidance (DHT Draft Guidance), discussed in our special report “2021 FDA Year in Review.” FDA’s issuance of these draft guidances represent a broader recognition of the important role that digital health technologies (DHTs) may play in modernizing the conduct of research.
As the Draft Guidance notes, many clinical trials already include decentralized elements. For example, research-related laboratory tests are often conducted by clinical laboratories that are remote from traditional trial sites, and advances in clinical care using telehealth technologies allow for fewer in-person visits to traditional trial sites and have expanded the types of trial-related data that can be obtained remotely from trial participants. FDA recognizes that by enabling remote participation, DCTs may enhance convenience for trial participants, reduce the burden on caregivers, and facilitate research on rare diseases and diseases affecting populations with limited mobility or access to traditional trial sites.
DCTs may not make sense in all cases, however. FDA’s guidance generally notes that fully decentralized trials, where all study activities take place at locations other than traditional trial sites, may be appropriate for investigational products that are simpler to administer or use, have well-characterized safety profiles, and do not require complex medical assessments. Conversely, hybrid decentralized clinical trials, where some trial activities are performed at traditional clinical trial sites and some are performed at other locations, may be appropriate where the administration of an investigational product or a complex medical assessment requires the subject to visit a clinical trial site, but certain follow-up assessments still can be performed remotely through online patient-reported outcome measures, telehealth or in-home visits, or by local healthcare providers (HCPs) not directly involved in the conduct of the clinical trial.
FDA also offers guidance on specific topics for implementing DCTs, specifically:
- DCT design
- Remote clinical trial visits and clinical trial-related activities
- Use of DHTs
- Sponsor and investigator roles and responsibilities
- Informed consent and institutional review board (IRB) oversight
- Investigational products in DCTs
- Packaging and shipping investigational products
- Safety monitoring plans
- Use of software in DCTs.
Sponsors, contract research organizations, investigators, and other stakeholders such as developers of DCT technologies or services should consider the recommendations in the Draft Guidance in connection with the design and implementation of DCTs and DCT-supporting technologies and services, as applicable.
DCT Design
By their nature, DCTs may involve a network of locations where trial personnel and local HCPs perform trial-related services, all under the oversight of the investigator. For inspection purposes, FDA expects a single physical location to be identified on Form FDA-1572 or in the investigational device exemption (IDE) application, as applicable, where all trial-related records for participants under the investigator’s care can be reviewed and all trial personnel can be interviewed.
In addition, FDA encourages sponsors to consult the applicable FDA review division when planning non-inferiority DCTs due to potential challenges in calculating non-inferiority margins presented by the variability and precision of data obtained in a DCT compared against data obtained in a traditional clinical trial. Such challenges may arise particularly in situations where trial participants are responsible for performing their own physiological tests or when local HCPs perform research-related assessments as part of routine clinical practice.
Remote Clinical Trial Visits and Clinical Trial-Related Activities
FDA states that, as a general matter, investigators can consider telehealth visits so long as no in-person interaction is needed, but FDA expects that the protocol specify which visits may be conducted via telehealth and which require the participant to either be seen at a traditional trial site or otherwise be seen in-person by trial personnel who are sent to the participant’s home or other preferred location. Where appropriate, trial personnel and participants should be trained on how to conduct or participate in a telehealth visit.
For telehealth visits, the investigator should confirm the trial participant’s identity, and sponsors and investigators can consider existing digital identity guidelines, such as the National Institution of Standards and Technology (NIST) Special Publication 800-63A: Enrollment and Identity Proofing Requirements, when developing and implementing an identity verification plan. In addition, case report forms and other documentation should be completed and should include the date and time of the visit.
FDA notes that, in certain situations, in-person visits may also be conducted by local HCPs who are not part of the trial personnel but are located close to the participant. In such situations, the HCPs may be used to perform trial-related services on a fee-for-service basis, but the trial-related services should not require a detailed knowledge of the protocol or the investigational product and should not differ from services the HCP is qualified to perform in clinical practice. Conversely, trial-related activities that are unique to the research or require knowledge of the protocol or investigational product should only be performed by properly trained and qualified trial personnel.
FDA also expects the trial protocol to specify how adverse events identified remotely will be evaluated and managed, as well as how care for adverse events that require urgent or in-person attention will be provided.
Digital Health Technologies
Pursuant to its August 2021 Prescription Drug User Fee Act (PDUFA) VII commitment to publish guidance on the use of DHTs in both traditional and decentralized clinical trials, discussed in our special report “2021 FDA Year in Review,” FDA also addresses the use of DHTs to allow transmission of data from trial participants, wherever they are located. FDA encourages sponsors, clinical investigators, and others measuring clinical events and characteristics in DCTs to review FDA’s recommendations in its DHT Draft Guidance. In any event, FDA expects sponsors to ensure that DHTs used in DCTs are available and suitable for use by all participants, including by providing DHTs to participants who do not already have protocol-specific DHTs in situations where the protocol permits participants to use their own DHTs.
Roles and Responsibilities
Sponsors
FDA notes that sponsor responsibilities are the same in DCTs and traditional site-based clinical trials, and that sponsors should ensure proper coordination of all decentralized activities. To account for multiple sources of data collection, FDA expects that a data management plan (DMP) will include information regarding:
- Data origin and data flow from all sources to the sponsor, which can take the form of a data flow diagram where appropriate.
- Methods used for remote data acquisition from participants, personnel, and contracted service providers such as clinical laboratories or local HCPs who perform trial-related activities.
- A list of vendors for data collection, handling and management.
In addition, sponsors should ensure that the protocol describes how operational aspects of the DCT will be implemented, including descriptions regarding scheduled and unscheduled visits, transmission of reports on activities performed at other locations, how the investigational product will be delivered to participants and accountability therefor, and safety monitoring and management of adverse events.
FDA also expects sponsors to prepare trial monitoring plans for DCTs that describe how monitoring will be implemented, specify the frequency of reviews and note any unique aspects related to monitoring DCT procedures.
Investigators
FDA encourages investigators to only enroll as many trial participants as they can appropriately manage in a DCT context, and notes that videoconferencing and other technologies may be useful for overseeing trial personnel performing trial-related activities at other locations (e.g., when photographing lesions or fitting wearable devices).
With respect to trial-related activities delegated to local HCPs, FDA generally advises that, for drug investigations, local HCPs who perform trial-related services that are part of routine clinical practice and where detailed knowledge of the investigational product, protocol and other study documentation is not necessary should not be listed on Form FDA-1572 as sub-investigators. For device investigations, the same category of local HCPs should not be included in the IDE list of investigators. In either case, however, FDA expects investigators to maintain a task log of local HCPs who perform trial-related activities and make the task log available to FDA during inspections. The task log should:
- Include the names and affiliations of the local HCPs, a description of their roles and assigned tasks, the dates they are added to the log, and location where activities are conducted.
- Be signed and dated by the investigator when initially created and updated as new local HCPs are added.
For trial protocols that require laboratory services, FDA generally recommends the use of a designated central laboratory, but the agency recognizes that some protocols may permit a variety of clinical laboratories local to the participant to perform laboratory services. FDA notes that while local laboratory facilities may be adequate for routine, well-standardized clinical tests, research specimens could be collected by remote trial personnel, local HCPs or clinical laboratory facilities local to the participant and sent to the designated facility for processing. All clinical laboratory facilities used in a DCT should be listed on Form FDA-1572 (for drug investigations) or the investigational plan for device studies under an IDE.
Informed Consent and IRB Oversight
FDA states that stakeholders may consider obtaining informed consent remotely in DCTs, subject to IRB oversight to ensure the process is adequate and appropriate. FDA recommends the use of a central IRB to promote efficient review and oversight of the DCT. In addition to meeting all applicable regulatory requirements, the informed consent process must include notifying participants of appropriate contacts for answers to questions about the research or research subject rights and research-related injuries. The informed consent should also describe who will have access to the trial participant’s health information.
Investigational Products in DCTs
For drug and biological investigational products, the appropriateness of administration outside of a traditional trial site depends on the complexity and nature of the investigational product itself. For complex administration procedures and high-risk drugs and biologics, in-person supervision by the investigator at a trial site may be required. In addition, drugs and biologics that require special handling, shipping or storage conditions may not be appropriate for shipment outside of the trial site. Alternatively, it may be appropriate for local HCPs or remote trial personnel to administer investigational products that do not involve specialized monitoring after administration and have well-characterized safety profiles. If investigational products will be administered outside of a traditional trial site, sponsors should estimate the urgency and complexity of care that may be needed based on the safety and risk profile of the drug or biologic, and investigators should take steps to ensure that participants have local access to appropriate levels of care.
Similar considerations are present for medical device investigational products. If the device is suitable for self-use (e.g., over-the-counter devices) and does not pose significant safety risks, remote use by trial participants without direct oversight by the investigator may be appropriate. However, if the device is not intended for self-use or poses significant safety risks, administration by qualified trial personnel with direct investigator oversight may be appropriate. FDA notes that certain follow-up procedures related to more complex devices may be performed by local HCPs or trial personnel via telehealth visits (where appropriate) or in-person at the participant’s home or local healthcare facility.
Packaging and Shipping Investigational Products
For DCTs in which investigational products will be distributed directly to participants at their locations, FDA states that sponsors should describe in the protocol how the physical integrity and stability of the investigational product will be maintained during shipment, how investigators will track and document that trial participants receive the investigational product, and the procedures that investigators or participants should use to return or dispose of the investigational product. Further, shipping containers should include clear instructions for handling, storing and returning the investigational products, and DCT personnel should be trained on these procedures and how to appropriately document them.
FDA notes that a central distribution service may be used to ship the investigational product directly to trial participants, and that investigators or delegated trial personnel must control the release of the investigational product by the distributor, monitor receipt and use by the trial participant, and monitor return or disposal of any unused investigational product as directed by the sponsor.
Safety Monitoring Plans
As with traditional clinical trials, FDA expects sponsors to implement safety monitoring plans for DCTs that describe how participants are expected to respond to and report adverse events, including where to seek medical assistance locally and where to receive follow-up care. In addition, the safety monitoring plan should pre-specify if and when telehealth visits or in-person visits will be scheduled with trial personnel or local HCPs to collect safety data and describe the type of information that will be collected by a DHT, how that information will be used and monitored, and the actions trial participants or personnel should take in response to abnormal findings or electronic alerts. Where routine safety monitoring involving laboratory testing and imaging at local clinical laboratory facilities is permitted by the protocol, investigators should ensure that they promptly receive reports of these services and review them in a timely manner.
If significant safety risks emerge related to remote administration or use of the investigational product, FDA states that sponsors must discontinue remote administration or use, notify FDA, the IRB, and all investigators who have participated in the trial, and determine whether the trial should continue.
Software Used in Conducting DCTs
Software can be used to support DCTs in several respects. For example, software can be used to manage electronic informed consent, capture and store reports from remote trial personnel or local HCPs or clinical laboratories, manage electronic case report forms (eCRFs), schedule trial visits and other DCT-related activities, track investigational products shipped directly to participants, sync information collected by DHTs, and facilitate communication between DCT personnel and trial participants. FDA expects that trial personnel, local HCPs and trial participants who use software in connection with a DCT will be appropriately trained on how to use such software.
Where local HCPs perform trial-related activities, FDA states that data from those activities can, among other mechanisms, be submitted for inclusion in trial records directly into the eCRFs or through secure data transfer methods to investigators, who must then enter the trial-related data into the eCRF. Where remote trial personnel or local HCPs submit trial directly into the eCRF, the same individuals should be included in the sponsor’s list of authorized data originators.
Any software program used to produce or process DCT records required by the Federal Food, Drug, and Cosmetic Act and FDA regulations are subject to 21 CFR Part 11 and must ensure data reliability, security, privacy and confidentiality. While FDA notes that real-time video interactions, including telehealth, are not considered electronic records and are not subject to 21 CFR Part 11, FDA nevertheless expects stakeholders to ensure the privacy and security of telehealth visits and to document the visits, including in systems compliant with 21 CFR Part 11 if captured electronically.
Conclusion
DCTs have the potential to enhance convenience for trial participants, reduce the burden on caregivers, and facilitate research on rare diseases and diseases affecting populations with limited mobility or access to traditional trial sites. They may also help improve trial participant engagement, recruitment, enrollment and retention of a meaningfully diverse study population. However, DCTs present special considerations related to coordination of trial activities among individuals and facilities in multiple locations that are not traditional clinical trial sites. The Draft Guidance provides helpful recommendations for sponsors, investigators and other stakeholders regarding implementation of DCTs to advance drug and device development.
Sponsors, investigators and other stakeholders that conduct DCTs should consider submitting comments to the Draft Guidance (Docket No. FDA-2022-D-2870). FDA recommends that the public submit comments by August 1, 2023, to ensure that FDA considers them prior to issuing final guidance.

EU Commission Adopts New Merger Simplification Package
ARTICLE / CLIENT ALERT
EU Commission Adopts New Merger Simplification Package
May 12, 2023
Read time: 8 min
The EU Commission has adopted a legislative package to further streamline the simplified merger control procedures within the European Union
On April 20, 2023, the EU Commission (Commission) adopted and published a package to simplify the procedures for reviewing concentrations under Regulation (EC) 139/2004 of January 20, 2004 (European Union Merger Regulation – EUMR). This package includes a set of three materials comprising (i) a revised Merger Implementing Regulation (Implementing Regulation), (ii) a Notice on Simplified Procedure (Notice), and (iii) a Communication on the Transmission of Documents to the Commission (Communication). The new notification forms (Form CO, Short Form CO, Form RS and Form RM) are also provided as Annexes to the Implementing Regulation.
The core objective of the package is to simplify merger review procedures, with a targeted 25% reduction on reporting requirements. This evolution is more than welcome, especially in light of the very recent Regulation on foreign subsidies distorting the internal market (FSR) which recently entered into force, imposing additional burdens on M&A transactions. We discuss this recent entry into force of the new FSR in our last article, available here.
This new package intends to bring significant benefits for businesses and advisers in terms of easing preparatory work and related costs. Relieving this administrative burden lying on the parties to a concentration should hopefully speed up the approval process by the Commission. The new package will apply from September 1, 2023.
Background
In 2013, the Commission implemented an initial simplified package, to streamline the review process for unproblematic cases and to further reduce the amount of information required for notifications at EU level.
In order to assess its effectiveness, in 2016 the Commission initiated an evaluation of procedural and jurisdictional aspects of EU merger control. The 2023 merger simplification package concludes this process. Below, we highlight key takeaways for businesses and provide guidance on how best to follow the new requirements.
New Merger Simplification Package in a Nutshell
Expanded Scope of Application of the Simplified Procedure
The Notice keeps the four existing categories of transactions that already benefit from the simplified procedure namely extraterritorial joint ventures, no horizontal or vertical relationship between parties, minor horizontal or vertical relationships between parties and switch from joint control to sole control.
At the same time, the Notice introduces two new types of eligible concentrations, where under all plausible market definitions:
- The individual or combined upstream and downstream market shares of the merging parties are below 50%, the market concentration index (Herfindahl-Hirschman Index – HHI) is below 150, and the company with the smallest market share is the same in the upstream and downstream markets; or
- In a vertical relationship, the individual or combined upstream market share of the merging parties is below 30% and their combined purchasing share in the downstream market is below 30% of upstream inputs
The Notice explains that concentrations might fulfil the criteria for more than one category. The notifying parties could thus submit a notification on the basis of more than one category.
Certain cases could even qualify for a “super-simplified” procedure, for which parties can notify directly without pre-notification contacts. Referring to its own experience, the Commission considers that the following concentrations may be reviewed under this super-simplified procedure, in less than 25 working days:
- Two or more parties acquire joint control of a joint venture, provided that the joint venture has no current or expected turnover within the territory of the European Economic Area (EEA), and the parties concerned have not planned to transfer any assets within the EEA to the joint venture at the time of notification
- Two or more parties merge, or one or more undertakings acquire sole or joint control of another party, provided that none of the parties to the transaction are engaged in business activities in the same product and geographic market or in a relevant product market that is upstream or downstream from a product market in which any other party to the transaction is engaged
As most concentrations reviewed by the Commission are Phase 1 simplified decisions (e.g. approx. 80% of merger decisions in 2022), the extended simplified and super-simplified treatments should be a relief.
The Flexibility Clause
The Notice allows the parties to request that the Commission review certain concentrations under the simplified procedure, even if they do not satisfy the related conditions, with four specific situations provided for the “flexibility clause”:
- For horizontal overlaps, where the combined market shares of the parties are between 20%-25%
- For vertical relationships where the individual or combined upstream and downstream market shares of the parties remains below 35%
- For vertical relationships where the individual or combined market shares of the merging parties do not exceed 50% in one market and 10% in the other vertically related market; and
- For joint ventures with turnover and assets between EUR 100 million and EUR 150 million in the European Economic Area (EEA)
The categories above apply alternatively, but not cumulatively. However, and except for the joint venture clause, the notifying party may combine the application of the flexibility clause with the classical simplified treatment cases, when the concentration involves several markets. In other words, if for certain markets the simplified treatment applies and for other markets the Commission agrees to apply the flexibility clause, then the entire transaction would benefit from the simplified procedure.
Safeguards and Exclusions from the Simplified Procedure
The Notice also extends and clarifies the circumstances through which the Commission may investigate a case under the normal procedure. The Notice includes a non-exhaustive list of examples of types of concentrations that may be excluded from the simplified procedure. It also clarifies that the instance of one or more of the circumstances may be a reason for the Commission to inform the notifying parties that the simplified treatment is not suitable. In particular, three situations are relevant to mention:
- Joint ventures with negligible activities in the EEA (as falling under the simplified procedure cases and the flexibility clause), where horizontal overlaps or vertical relationships exist between the parties to the concentration
- Where one party to the concentration may have significant non-controlling shareholdings in companies active in the market(s) where another party to the transaction is active; and
- Where at least two parties to the transaction are present in closely related neighboring markets (i.e., when the products are complementary to each other or when they belong to a range of products that is generally purchased by the same set of customers for the same end use). This can occur where one or more of the parties holds an individual or combined market share of 30% or more in any product market in which there is not horizontal overlap or vertical relationship.
Transmission Requirements to the Commission
For efficiency purposes, the new merger simplification package seeks to “optimize” the exchange of information between notifying parties and the Commission. To facilitate this, the Communication streamlines the application and review of both simplified and non-simplified cases. For the former, the Implementing Regulation introduces a new “tick-the-box” Short Form CO, for the “super-simplified” categories of cases. For the non-simplified process, information requirements are reduced and clarified, with a new Form CO. Both forms are included in the Annexes to the Implementing Regulation. Besides the Form CO and Short Form CO, the Commission has also revised and streamlined the other filings, including the referral request of mergers to or from the Commission (Form RS) and the remedy proposal (Form RM).
More practically, the Communication now requires notifications to be sent electronically, and the package also implements the use of the Qualified Electronic Signature (QES). This increased adoption of digital correspondence is a direct, and welcome, consequence of the COVID-19 period of remote administration. Exceptionally the Commission will continue to accept notifications on paper, if it is agreed that signing documents with a QES is not feasible.
While it may prima facie appear that less information will be submitted with the notification forms, in fact the amount of information and internal documents that notifying parties will have to collect has not materially decreased. In certain domains, the information burden has increased, including more information required in the Form CO in respect of “pipeline products” under development.
Finally, it is welcome that the Commission may consider granting, in appropriate circumstances, waivers for additional categories of information.
How to Prepare for the Application of the New Simplified Package
Application of the New Merger Simplification package – Timetable
The Commission has published this new simplification package well in time before its entry into force, to allow companies, and outside counsel, to prepare for the new procedures. As mentioned above, the notifying parties will have to use the new forms and procedure as of September 1, 2023.
Until then, the current procedure and notification forms remain in force, although companies have the opportunity (and are encouraged) to initiate pre-notification contacts.
This new merger simplification package is welcomed by business, as it is intended to usher in quicker processing, faster transactions and, therefore, cost savings. It remains to be seen in practice whether it will lead to hoped-for increased legal certainty, and whether the companies will in fact obtain EU clearance decisions faster. This latter objective seems optimistic, considering that the duration of pre-notification in simplified cases has already been reduced to an average 18-19 day-duration, and that the Commission still has to consult the Advisory Committee before any decision is taken on a concentration.

Whistleblower Protection Act Update – Resolution of the German Federal Council (Bundesrat)
ARTICLE / CLIENT ALERT
Whistleblower Protection Act Update – Resolution of the German Federal Council (Bundesrat)
May 12, 2023
Read time: 6 min
Düsseldorf, May 12, 2023 – Today, the German Federal Council (Bundesrat) approved the act on the implementation of the Whistleblower Directive (“German Whistleblower Protection Act” – HinSchG), after several delays and convocation of the mediation committee. From the time the act is promulgated in the Federal Law Gazette, companies with 50 or more employees will be required to set up certain whistleblower systems within a specified period. The act will come into force one month after promulgation – expectedly in mid July 2023.
1. BACKGROUND
The aim of the German Whistleblower Protection Act (HinSchG) is to implement the so-called EU Whistleblower Directive (EU) 2019/1937 of October 23, 2019, for improved whistleblower protection and to create legal certainty when reporting or disclosing potential wrongdoing in companies and public authorities. The act regulates the protection of so-called “whistleblowers”, i.e. natural persons who have obtained information about violations throughout their professional activities and carry this information to designated reporting channels. In addition to persons who report breaches of Union law, the HinSchG also protects whistleblowers who report violations of national law.
2. WHO IS AFFECTED BY THE ACT?
In principle, whistleblower systems must be set up by legal entities in the private sector with at least 50 workers. All enterprises having up to 250 employees will be obliged to have implemented the requirements of the Whistleblower Protection Act by December 17, 2023, at the latest. Companies with more than 250 employees will be left with just one month from the promulgation of the HinSchG to implement it. The same applies to highly regulated companies pursuant to Section 12 para. 3 HinSchG, regardless of its number of employees, such as capital management companies or insurance companies. For listed companies, A.2 of the German Corporate Governance Code provides for a recommendation to set up a whistleblower system, which applies independently of the size or number of workers of the company.
3. OBLIGATIONS AND CONSEQUENCES FOR THE COMPANIES
Companies are required to establish and operate internal reporting channels for whistleblowers and to provide access to external reporting channels. Internal reporting channels which the workers can turn to, will be set up and operated by the employer itself or a third party entrusted by the employer (e.g., a law firm), see Section 14 para. 1 HinSchG. In an international group, “third party” may also be another group company. In this case, it must be ensured that that the implementation of a central reporting channel at a company of the group does not lead to any obstacles to access in comparison with a set-up of the channel directly in the same company. For example, it must be possible to report in the working language of the entrusting company. In case of entrusting a third party with the tasks of an internal reporting channel, the obligation to take appropriate measures to remedy any violations remains with the entrusting company, see Section 14 para. 1 sent. 2 HinSchG.
The employer is supposed to create incentives for employees to turn to the internally established channel as a preference in order to achieve fast processing and internal resolution of internal problems while also relieving the external channels.
At the same time, whistleblowers are encouraged to turn to the internal reporting channel if this is likely to be successful and there is no threat of retaliation. However, whistleblowers have the choice of using an internal reporting channel or reporting their information to an external channel – possibly also out of fear of a lack of anonymity. The HinSchG does not provide for any legal consequences for prioritizing the external reporting channel in a manner that deviates from the legislative intent.
External reporting channels are competent authorities that are authorized to receive reports. Such an external reporting channel is set up, for example, at the Federal Office of Justice or by the federal states in the respective state and local administrations. Internal and external reporting channel structures have in common that they are not required to set up anonymous reporting channels. However, anonymous reports must still be taken into account and processed.
The HinSchGt also prohibits companies from retaliation against whistleblowers. Even the threat or attempt to impose sanctions is prohibited. This applies towards suspension, dismissal, salary reduction, non-renewal of a fixedterm employment contract and any intimidation attempts on the part of the employer towards its employees. The HinSchG provides for an employee-protective reversal of the burden of proof, which in practice will not play a major role, at least in the main case of termination, due to the existing allocation of the burden of proof under the German Dismissal Protection Act (Kündigungsschutzgesetz). Only in case of terminations outside the scope of the German Dismissal Protection Act may this reversal of the burden of proof bring a relevant change. Pursuant to Section 36 para. 2 of the HinSchG, it is presumed that an occupational disadvantage following a report or disclosure constitutes retaliation. However, the reversal of the burden of proof only occurs if the person providing the information sets out the possible connection. In the event of a violation by the company, the whistleblower shall be entitled to compensation of the resulting damage.
If an employer who falls under the HinSchG does not set up an internal reporting channel, fails to operate it properly or takes retaliation, it commits an administrative offense. Violations of this kind can be punished under the HinSchG with a fine of up to EUR 50,000.00.
4. RECOMMENDATION TO COMPANIES
In order to avoid possible sanctions, the companies to which the HinSchG applies should now, at the latest, endeavor to establish appropriate reporting channels within the timeframe set by the German legislator.
Particular attention should be paid to the fact that the HinSchG will enter into force earlier than envisaged in the previous draft. The HinSchG enters into force one month after promulgation – in mid-June 2023.
In particular, international groups of companies and corporations should review the structure of its whistleblowing system, the arrangement and set-up of the individual reporting channel(s) as well as the related documentation against the background of the current legal developments. If group companies exist in different EU Member States, the differences in the implementation of the EU Whistleblower Directive in the respective Member States must be taken into account. We will, of course, be pleased to support you in the legal review and the implementation of technical solutions in compliance with the applicable best practice standards.
Sanctions for employers who have not set up an internal reporting channel may only be imposed after the transitional period of six months, but even before this point in time there is a risk that whistleblowers may immediately turn to external reporting channels.

HHS OIG Develops Toolkit to Analyze Telehealth Claims to Assess Program Integrity Risks
ARTICLE / CLIENT ALERT
HHS OIG Develops Toolkit to Analyze Telehealth Claims to Assess Program Integrity Risks
May 12, 2023
Read time: 12 min
On April 20, 2023, the United States Department of Health and Human Services Office of the Inspector General (HHS OIG) released a new toolkit designed to help analyze telehealth claims to assess federal healthcare program integrity risks. The toolkit is OIG’s latest action in its continued focus on telehealth services that OIG considers to be high risk. The toolkit is based on methodologies highlighted in OIG’s September 2022 data brief, which identified billing practices by Medicare providers that OIG was concerned posed a high risk to program integrity based on a review of Medicare fee-for-service claims data and Medicare Advantage data from March 1, 2020, through February 28, 2021 (OIG Data Brief). The September 2022 OIG Data Brief is discussed in detail in this prior On The Subject article.
OIG intends for the toolkit to be used by public and private parties, including Medicare Advantage plan sponsors, private health plans, State Medicaid Fraud Control Units, and other federal healthcare agencies to analyze program integrity risks and identify providers whose billing may pose a high risk and warrant further scrutiny.
The toolkit is divided into two components for analyzing potential program integrity risk associated with telehealth claims: (1) steps for analyzing telehealth claims and (2) program integrity measures.
- Steps for analyzing telehealth claims. The first toolkit component consists of OIG-recommended steps for reviewing telehealth claims data.
1.1. Review program policies. OIG notes that, as a starting point, organizations need to be aware of the specific payment and coverage policies of the program in which they participate. Program requirements for telehealth coverage and claims data vary across programs. The toolkit was based on Medicare fee-for-service payment and coverage policies in place during the first year of the COVID-19 pandemic. While many of these policies were extended through December 31, 2014, by the 2023 Consolidated Appropriations Act (CAA 2023), certain telehealth policies will end with the end of public health emergency for COVID-19 on May 11, 2023. We covered the CAA 2023 telehealth extensions in a prior On the Subject article.
1.2. Collect claims data. The toolkit is designed to be used for claims data from individual providers, including physicians and non-physician practitioners. OIG expressly does not intend the toolkit to be used for claims data from institutions, such as hospitals and nursing homes. The toolkit focuses on the limited set of services that may be provided to Medicare beneficiaries via telehealth and certain virtual-care services not designated by CMS as telehealth services, including e-visits, virtual check-ins and remote monitoring. Telehealth services may include office visits with primary care providers or specialists, behavioral health services, and preventive services. OIG used modifiers or place-of-service codes to identify the services provided via telehealth, which are billed using codes that are also used for in-person services. (A list of services that can be provided via telehealth is available here.) The other set of virtual care services are billed using codes specifically designated for the services, with no in-person counterpart. (A list of such virtual care services is available in an appendix to the toolkit.)
1.3. Conduct quality assurance checks. OIG recommends conducting internal quality assurance checks on the data being analyzed. OIG identified the following steps for testing the completeness and accuracy of the data: (1) identification number of the provider who rendered the service, (2) identification number of the billing provider associated with the service, (3) identification number for the patient who received the service, (4) date of the service, (5) procedure code billed, (6) quantity of services units billed, and (7) modifiers or place-of-service codes attached to the service. The toolkit also includes a reminder that data should be reviewed to check for and remove any errors.
1.4. Analyze data to identify program integrity risks. Once the data in step 1.3 is gathered and checked for quality, users should undertake an analysis to review the data to identify potential program integrity risks. The toolkit specifically identifies seven program integrity measures to be used for evaluation (discussed in detail in Section 2). However, OIG cautions that these measures are intended to be a starting point, not an exhaustive lists of all potential program integrity risks associated with claims for telehealth services. OIG further cautions that the thresholds for categorizing what constitutes a high-risk claim should be tailored according to the specific program involved and the goals of the review. OIG also notes that the toolkit was intentionally designed with “incident to” billing in mind.
1.5. Interpret the results of the analysis. As data analysis is completed, users can use the toolkit to benchmark their results against those flagged by OIG as potential threats to program integrity. This phase may result in the identification of overpayments or the need to reevaluate how a provider bills for telehealth services. Of course, exceeding a potential threshold noted in the toolkit is not itself evidence of fraud and abuse. Once a concern is identified, further investigation of the facts and circumstances involved would be necessary to determine the extent of any potential non-compliance and remediation required. - Program integrity measures. Once an organization has analyzed its telehealth claims data, the second toolkit component is designed to help the organization determine if its data represent program integrity risk. Here, OIG has developed a three-pronged approach: (1) measure, (2) analysis and (3) threshold. “Measure” refers to the particular type of program integrity risk to be reviewed, “analysis” explains how to calculate the measure and “threshold” provides guidance about the level of activity that OIG views as a potential risk to program integrity. The toolkit contains seven measures, each focused on different billing activities that may raise program integrity concerns. Many of the measures can and should be tailored to the specific goals of the user and includes either limiting analysis to those providers who provide a minimum number of telehealth services, or setting a specific threshold in accordance with the compliance goals of the organization. OIG recommends that users review measures of central tendency (e.g., mean and median) and the distribution of the data, including outliers, to set the threshold at an appropriate level to suit the goals of the review and data.
2.1. Billing telehealth services at the highest, most-expensive level for a high proportion of services. This measure is used to identify providers who routinely bill telehealth services at the highest, most-expensive level. Such a pattern may indicate that a provider is upcoding telehealth services claims. The toolkit recommends identifying services that are billed at different rates for higher-level service. (For example, the toolkit notes that there are five Medicare codes for established patient office visits, with the highest being reimbursed at eight times the rate of the lowest service level.) Next, the toolkit suggests determining the percentage of a particular provider’s services that were billed at the highest level. In the OIG Data Brief, OIG considered Medicare providers to be high risk if they billed 100% of their telehealth services at the highest level of service.
2.2. Billing a high number of hours of telehealth services. The toolkit next includes a measure to identify providers who bill a high average number of hours per telehealth visit, which may indicate that a provider is billing for medically unnecessary services or for services not rendered at all. The toolkit’s approach categorizes a “visit” as all of the telehealth services rendered to a patient one-for-one date. In the OIG Data Brief, high-risk providers were those that billed for an average of more than two hours of telehealth services per visit, excluding “extra-long” services and psychological testing and evaluation. The toolkit also highlights checking for the so-called “impossible day,” such as instances where providers billed for 25 hours of services in a single day. OIG notes that impossible-day analysis is not a good fit in instances where incident to billing is permitted, but is another tool in the toolkit when evaluating providers who bill for abnormally high hours of telehealth services. OIG again notes that users may change this threshold to fit different needs and data.
2.3. Billing telehealth services for a high number of days in a year. Another measure in the toolkit is for identifying providers who billed telehealth services for a high number of days per year. This is calculated by counting the total number of unique dates in a year that a provider billed at least one telehealth service. In the OIG Data Brief, OIG considered a provider to be high risk if they billed more than 300 days in a year, as the median for all providers who billed Medicare for telehealth services was 26 days.
2.4. Billing telehealth services for a high number of patients. This measure seeks to identify providers who bill for a high number of unique patients, which OIG indicates may suggest that the provider is billing for services not rendered. The toolkit suggests calculating this measure by taking the total number of unique patients for whom at least one telehealth service was billed during a one-year time frame. In the OIG Data Brief, OIG considered providers who bill telehealth services for 2,000 or more beneficiaries in a one-year period to be high risk under this measure. For context, the 2,000 patient threshold is approximately 100 times the median of 21 beneficiaries for all providers who billed for telehealth Medicare services.
2.5. Billing multiple plans or programs for the same telehealth services for a high proportion of services. The toolkit provides a measure to capture providers who bill a high proportion of claims to multiple plans or programs for the same telehealth services. OIG states this may indicate that a provider is intentionally submitting duplicate claims. This analysis is conducted by identifying telehealth services that were billed to more than one program by matching information submitted to both programs and identifying the percentage of the provider’s claims that were submitted to more than one plan. For example, OIG’s analysis looked at providers who billed the same services to both Medicare Advantage and Medicare fee-for-service. OIG recognizes there are instances in which it is appropriate for a beneficiary to be enrolled in both programs, so this measure should be customized to account for such patients. In the OIG Data Brief, OIG determined that a high-risk provider was one who billed both Medicare Advantage and Medicare fee-for-service for more than 20% of their claims.
2.6. Billing for a telehealth service and then ordering medical equipment for a high percentage of patients. Another measure in the toolkit involves the relationship between providing services and ordering equipment for patients. The measure is used to identify providers who bill for telehealth services and subsequently order medical equipment and supplies for a high number of patients, which raises program integrity concerns because of its similarity to what OIG characterized as “known fraud schemes.” OIG’s concern is that providers may be ordering unnecessary medical equipment and supplies for patients. To identify high-risk providers using this measure, OIG suggests calculating the percentage of patients for whom a provider billed a telehealth service and then also ordered medical equipment and supplies. In the OIG Data Brief, OIG considered providers to be high risk where they billed for a telehealth service and then ordered medical equipment within three months of the telehealth visit more than 50% of the time. The median occurrence for providers billing for a telehealth service and then ordering equipment was 3%. OIG further noted that this analysis can be further customized to identify providers who billed audio-only telehealth services, which OIG suggests could indicate providers are cold calling Medicare beneficiaries to increase orders for medical equipment, supplies and services.
2.7. Billing for both a telehealth service and facility fee for most visits. The seventh toolkit measure is to identify providers that bill for both a telehealth service and facility fee for most of their visits. The facility fee (also known as an originating site facility fee) is allowable under Medicare where a healthcare facility hosts a patient on-site and the patient receives telehealth services from a provider located offsite. The provider performing the telehealth service then bills for the telehealth service separately. Medicare does not allow a provider to bill for both telehealth services and the facility fee. In the OIG Data Brief, OIG identified providers who billed at least 10 telehealth visits and billed for both the telehealth services and facility fees more than 75% of the time to be high risk. Most providers did not bill for both fees. OIG further noted that identifying providers who are part of the same medical practice and providers who are associated with one or more telehealth companies could further identify risky activity.
KEY TAKEAWAYS
- The toolkit takes OIG’s leveraging of data analytics to the next level by promoting the use of the toolkit’s analytical framework to identify providers who are billing outside of standards expected by the toolkit’s intended users (Medicare Advantage plan sponsors, private health plans, State Medicaid Fraud Control Units and other federal healthcare agencies). The adoption of the framework could result in further enforcement action against telehealth and other virtual-care providers.
- Telehealth and other virtual care providers, particularly those who bill Medicare fee-for-service and Medicare Advantage plans, should carefully review the toolkit in conjunction with their own internal compliance policies and procedures and consider incorporating related analyses as part of their compliance monitoring activities. The toolkit may offer opportunities to enhance and supplement existing compliance programs to stay up to date with OIG enforcement priorities.
- The toolkit can be used as an indication of OIG’s priorities for telehealth billing and program integrity enforcement reviews. Telehealth services and their relationship to program integrity efforts remain an area of focus for OIG.

Florida Adds a New Twist to Consumer Privacy Patchwork
ARTICLE / CLIENT ALERT
Florida Adds a New Twist to Consumer Privacy Patchwork
May 10, 2023
Read time: 9 min
On May 9, 2023, the Florida legislature passed the Florida Digital Bill of Rights (FDBR), which adds a new twist to the growing body of state consumer privacy laws. The bill now heads to Governor Ron DeSantis’ desk, and it is anticipated that he will sign the bill into law. While the FDBR is modeled off of consumer privacy laws like those in Virginia, there are a number of unique aspects of the bill that would make it an outlier, including as related to the scope of companies that will be regulated under the FDBR. Assuming that the bill is signed into law, it will go into effect on December 31, 2023.
Below we provide an overview of some of the key aspects of Florida’s new consumer privacy law.
To Whom Does the FDBR Apply?
Most of the FDBR applies to businesses that meet the following requirements:
- Is organized or operated for the profit or financial benefit of its shareholders or owners;
- Conducts business in Florida;
- Collects personal data about Florida consumers, or is the entity on behalf of which such information is collected;
- Determines the purposes and means of processing personal data about Florida consumers alone or jointly with others;
- Makes in excess of $1 billion in global gross annual revenues; and
- Satisfies at least one of the following:
- Derives 50% or more of its global gross annual revenues from the sale of advertisements online, including providing targeted advertising or the sale of ads online;
- Operates a consumer smart speaker and voice command component service with an integrated virtual assistant connected to a cloud computing service that uses hands-free verbal activation. For purposes of this sub-subparagraph, a consumer smart speaker and voice command component service does not include a motor vehicle or speaker or device associated with or connected to a vehicle that is operated by a motor vehicle manufacturer or a subsidiary or affiliate thereof; or
- Operates an app store or a digital distribution platform that offers at least 250,000 different software applications for consumers to download and install.
On its face, as a result of the $1 billion revenue threshold and the requirements in section (6) above, the FDBR likely will apply to only the largest of tech companies.
However, as discussed below, one part of the FDBR applies to businesses that meet the requirements of (1), (2) and (3) above. Those companies are prohibited from selling sensitive data without the prior consent of the individual to whom the data relates.
Who Is a “Consumer”?
In the FDBR, a “consumer” is an individual who is a resident of or is domiciled in Florida and acting only in an individual or household context. This means that employees and B2B contacts are expressly excluded from the definition of “consumer.”
What Is “Personal Data”?
“Personal data” in the FDBR is “any information, including sensitive data, which is linked or reasonably linkable to an identified or identifiable individual. The term includes pseudonymous data when the data is used by a controller or processor in conjunction with additional information that reasonably links the data to an identified or identifiable individual. The term does not include deidentified data or publicly available information.”
This definition of “personal data” largely tracks the definitions in other state consumer privacy laws like those in Virginia or Connecticut.
Who Can Enforce?
The Florida Department of Legal Affairs has exclusive enforcement authority, and there is an express provision disclaiming any private right of action. Before initiating any enforcement proceeding, the Florida Attorney General has the discretion to give a 45-day cure period. However, if the violation relates to the information of a known child, there is no cure period permitted.
The Florida Attorney General can seek damages of up to $50,000 per violation, making it unquestionably the most punitive of the state consumer privacy laws to date.
Who Is Exempt?
The exemptions to the FDBR closely mimic those of other state privacy laws. For example, personal information is covered by laws such as the Health Insurance Portability and Accountability Act (HIPAA), the Children’s Online Privacy Protection Act (COPPA), the Gramm-Leach-Bliley Act, the Family Educational Rights and Privacy Act and a litany of other federal laws.
In addition, the FDBR does not apply to government entities, nonprofit organizations or higher education institutions.
The FDBR also exempts the use of personal data for certain specific purposes, such as compliance with the law, preventing fraud or injury to others and defending legal claims, just as in other state consumer privacy laws.
What Obligations Are Imposed?
Under the FDBR, controllers must:
- Limit the purpose of processing personal information to that which is reasonably necessary and proportional;
- Take steps to implement reasonable safeguards for the personal information within their control;
- Refrain from discriminating against consumers for exercising their rights and from processing personal information in violation of federal laws that prohibit discrimination;
- Be transparent in their reasonably accessible, clear and meaningful privacy notice; and
- Ensure contracts control relationships with their processors (note: the law itself details the minimum necessary provisions of these contracts).
What Consumer Rights Are Created by the FDBR?
Controllers must provide a set of customer rights that are broader that the standard state consumer privacy suite of rights, including:
- Access rights, including a right to confirm whether the controller is processing any data at all;
- Correction rights, accounting for the nature of the data;
- Deletion rights (with respect to the data provided by or about the consumer);
- Data portability rights;
- Opt-out rights related to the sale of personal information, targeted marketing and profiling (automated decision-making that could have significant legal effects such as related to housing, drinking water, credit, etc.);
- Opt-out of the collection of sensitive data;
- Opt-out of the collection of personal data through voice recognition features; and
- Appeal rights.
Sensitive Personal Information
Under the FDBR, “sensitive data” is personal data that includes information such as racial/ethnic origin, religious beliefs, mental or physical health diagnosis, information about a person’s sex life, sexual orientation, citizenship or immigration status, genetic or biometric information used to uniquely identify an individual, personal data collected from a known child (under the age of 18) and precise geolocation (location within a radius of 1,750 feet). A unique aspect of this definition is that a “known child” is an individual under the age of 18, making it an outlier under state consumer privacy laws.
Under the FDBR, a controller may not process (including collection) sensitive data without obtaining the consumer’s consent or, in the case of a child, complying with COPPA.
In addition, and as noted above, any for-profit business operating in Florida and collecting consumer data may not sell sensitive data absent consent from the data subject.
Response to Consumer Inquiries
The FDBR also contains a wrinkle with respect to responding to consumer data requests. Under the FDBR, controllers must respond to a consumer personal data request within forty-five (45) days of receipt of the request, with a fifteen-day (15) day extension available. If a consumer appeals a decision of the controller to deny a consumer request, the appeal response must be delivered within sixty (60) days. Interestingly, however, there is no requirement to inform a consumer of their ability to escalate to the Florida Attorney General.
Data Protection Impact Assessments
As with other state consumer privacy laws, under the FDBR, controllers will need to document impact assessments before they engage in a number of different processing activities, including: (i) processing for targeted advertising; (ii) sale of personal data; (iii) processing of personal data for profiling if the profiling presents a reasonably foreseeable risk of legal, deceptive, discriminatory, financial, reputational or physical harms; (iv) processing sensitive data; and (v) a catch-all category of any processing that presents a heightened risk of harm to consumers.
The FDBR allows for the use of impact assessments done under other state laws to count towards the requirements of the FDBR.
What Are the Unique Aspects of the FDBR?
Just when we were starting to get some uniformity, the FDBR very much breaks that mold. In addition to the differences discussed above with respect to the scope of businesses regulated under the FDBR, opt-outs from voice recognition and the scope of the definition of “known child” (i.e., under 18), the FDBR has several other unique provisions, including:
- If a business maintains a self-service mechanism that allows consumers to correct their own information, that business can deny a correction request and direct the consumer to the self-service mechanism.
- Search engines are required to provide a “plain language” description of the “main parameters” used to determine how results are provided to consumers.
- If a business sells consumer data, there may be two different “NOTICE” provisions on their website: (i) a notice that sensitive data may be sold and (ii) a notice that biometric personal data may be sold.
- There is a two-year retention period placed on consumer data, albeit subject to a number of exceptions, including, e.g., preservation for legal requirements, internal uses and continuing to provide goods and services to the consumer.
When Does the FDBR Take Effect?
The FDBR comes into effect on December 31, 2023.
***
Creating a successful and effective, comprehensive privacy program for your organization requires a thorough understanding of both the relevant legal obligations and the personal information subject to compliance. Setting up a program that is prepared to respond to various state privacy laws as they come into effect will save organizations time in the long run, especially as many of these laws reflect one another.
If you have questions or need assistance in readiness work for the new state consumer laws, please contact your regular McDermott lawyer or reach out to David Saunders.
Check out our additional coverage on new state consumer privacy laws:
Tennessee Joins the Fray as Legislature Passes Consumer Privacy Law
Consumer Privacy Law Comes to Big Sky Country as Montana Passes New Law
Indiana Passes Consumer Privacy Bill
Iowa’s New Privacy Law: The Basics
Colorado Finalizes Sweeping New Privacy Rules; Iowa Joins the Fray
Preparing for New Consumer Privacy laws in Colorado, Connecticut and Utah

CMS Unwinds Waivers as the COVID-19 PHE Comes to an End
ARTICLE / REPORT
CMS Unwinds Waivers as the COVID-19 PHE Comes to an End
May 10, 2023
Read time: 2 min
At the onset of the COVID-19 PHE, CMS was permitted to issue several temporary emergency statutory and regulatory waivers to help providers appropriately respond to the pandemic. On May 1, 2023, the Secretary released a memo confirming that upon termination of the PHE on May 11, 2023, most all of the Section 1135 and related waivers enacted during the PHE would also terminate. This announcement also contained short summaries of the expirations of emergency waivers issued during the PHE related to long-term care (LTC) and acute and continuing care (ACC) providers. Certain regulations and policies will be modified to correspond with the end of the PHE. Others, such as the acute hospital and home initiative and telehealth flexibilities, have been extended to survive the end of the PHE and remain effective until December 31, 2023, or the dates otherwise mentioned. All affected providers and facilities are expected to comply with the new requirements according to the timeframes outlined by CMS.
CMS also highlighted a few areas in which it plans to use enforcement discretion to effectively extend regulatory flexibilities. Updated charts below summarize key waivers and the changes that take place at the end of the PHE on May 11, 2023.

Teleprescribing of Controlled Substances Temporarily Extended Beyond PHE – What’s Next?
ARTICLE / CLIENT ALERT
Teleprescribing of Controlled Substances Temporarily Extended Beyond PHE – What’s Next?
May 10, 2023
Read time: 7 min
The US Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) are extending telehealth flexibilities that allow providers to prescribe controlled substances. While the extension is in place, the DEA indicated that, in light of the 38,000 comments it has received, it will be further evaluating its recently proposed rules for post-PHE telemedicine prescription of controlled substances. Learn what stakeholders need to monitor during this time and what may be next from the DEA.
On May 10, 2023, the DEA and SAMHSA issued a temporary rule extending telemedicine flexibilities adopted during the COVID-19 public health emergency (PHE). The temporary rule will allow telemedicine providers to continue prescribing controlled substances through November 11, 2023, or six months beyond the end of the PHE. The PHE is ending on May 11, 2023, and the temporary rule will go into effect at that time. The DEA and SAMHSA issued this press release along with the announcement.
The restrictions in place before the COVID-19 PHE required a telemedicine provider to perform an in-person medical evaluation of a patient prior to prescribing a controlled substance (with certain limited exceptions). Without the temporary rule extending the telemedicine flexibilities, those restrictions would have gone into effect on May 12, 2023.
While the extension is in place, the DEA indicated that, in light of the 38,000 comments it has received, it will be further evaluating its recently proposed rules for post-PHE telemedicine prescription of controlled substances.
KEY TAKEAWAYS
- Current flexibilities that allow providers to prescribe certain controlled substances via telemedicine (without an in-person visit) will continue through November 11, 2023.
- The temporary rule also provides a one-year grace period for any practitioner-patient “telemedicine relationship established via COVID-19 telemedicine prescribing flexibilities” on or before November 11, 2023. This allows telemedicine providers with established relationships to continue prescribing controlled medications through November 11, 2024.
- The DEA is continuing to review the more than 38,000 comments it received on two recently proposed rules (the General Telemedicine Rule and the Buprenorphine Rule). The rules would have established additional potential pathways for the prescription of certain controlled substances in limited quantities via telemedicine without an initial in-person medical examination.
- It is unclear if the DEA will revisit an effort to create a special registration process, which it declined to do through the two previously proposed rules and did not address in this temporary rule.
BACKGROUND
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (Ryan Haight Act) requires a telemedicine provider to perform an in-person medical evaluation of a patient prior to prescribing a controlled substance to that patient unless an exception applies (21 U.S.C. § 829(e)(1)). The Ryan Haight Act includes a broad exemption to the in-person medical evaluation requirement for the delivery, distribution or dispensing of a controlled substance by a practitioner engaged in the “practice of telemedicine” (21 U.S.C. § 829(e)(3)). However, despite the apparent flexibilities for providers who are delivering services via telemedicine, the “practice of telemedicine” is defined quite narrowly. Specifically, it is defined as an encounter that is provided through a “telecommunications system” (currently defined under 42 CFR § 410.78(a)(3) to require a live audio-visual encounter except with respect to certain mental health treatments under special circumstances, although there is no statutory definition) in one of the following seven circumstances:
- The patient is being treated in and is physically located in a hospital or clinic;
- The patient is being treated by and in the physical presence of another practitioner;
- The patient is being treated by a provider employed by the Indian Health Services;
- The treatment is occurring during a PHE declared by the secretary of the US Department of Health and Human Services (HHS) involving locations and controlled substances designated by the Secretary of HHS and the US Attorney General;
- The patient is being treated by a practitioner who holds a special registration, requirements for which are set forth in 21 U.S.C. § 831(h);
- There is a medical emergency, and the patient is being treated by an employee of the Veterans Health Administration (provided that certain additional requirements are met) or
- The patient is being treated under other circumstances as set forth in regulation as determined jointly by the HHS Secretary and the US Attorney General to be consistent with effective controls against diversion and otherwise consistent with the public health and safety (21 U.S.C. § 802(54)).
The controlled substance-prescribing flexibilities invoked in January 2020 in response to the PHE under subparagraph D were set to end with the termination of the PHE on May 11, 2023. Providers and others have long awaited the development of the “special registration” process described in subparagraph E, which would require the DEA to establish the circumstances and procedures under which a special registration could be issued under the Ryan Haight Act. In the 14 years since the Ryan Haight Act’s passage, the DEA has failed to implement such a process, even though Congress imposed an October 2019 deadline in the SUPPORT for Patients and Communities Act for the promulgation of final regulations. In the proposed rules issued in February 2023, the DEA opted not to implement the registration process and instead invoked its authority under subparagraph G.
Under the February proposed rules still under review by the DEA, telemedicine providers would no longer be able to prescribe Schedule II controlled substances or narcotics without an in-person evaluation. Telemedicine providers would be able to prescribe a 30-day supply of Schedule III–V controlled substances or buprenorphine as medication for opioid use disorder without an in-person evaluation, but an in-person evaluation (further explained below) would be required for any renewal of such prescriptions. An exception for provider-patient relationships formed via telemedicine during the PHE would allow telemedicine providers to continue prescribing Schedule II–V controlled medications through November 7, 2023. After that, an in-person evaluation would be required to continue prescribing. An in-person evaluation may be conducted by the prescribing telemedicine provider, by another DEA-registered provider who participates in a real-time audio-visual telemedicine consultation with the patient and the prescribing provider, or by another DEA-registered provider who has performed an in-person evaluation of the patient and refers the patient to the prescribing provider. (See our Special Report: DEA Proposes Limited Post-PHE Telemedicine Prescription of Controlled Substances for more details on the proposed rules.)
The DEA faced significant pushback regarding the pathways provided in the February proposed rules, including from federal lawmakers. This pushback included a record 38,000 comments. Many stakeholders highlighted that the requirement for an in-person evaluation would make it more challenging for patients who face significant barriers to accessing care without telemedicine to continue receiving the controlled medications they need.
DEA COMMENTARY
In this temporary rule, the DEA acknowledged comments from stakeholders in support of the extension of the PHE telemedicine flexibilities for relationships established both during and following the end of the PHE. The DEA agreed that immediately ceasing the PHE telemedicine flexibilities would jeopardize patient care, including from patient backlogs, as practitioners might be inundated with requests for in-person medical evaluations. The DEA indicated that a six-month extension of the flexibilities, allowing the continuation of practitioner-patient telemedicine relationships established through November 11, 2023, would support patient care while still being an effective control against diversion. The DEA indicated that it did not extend the flexibilities for longer than six months in an effort to disincentivize the creation of telemedicine companies that may seek to engage in problematic prescribing practices.
The DEA recognized that many telemedicine companies are patient-centered prescribing practices operating in good faith. It stated that it looks forward to working with such companies to further enhance patient access to needed medications when telemedicine prescriptions are appropriate and issued in the usual course of professional practice following bona fide medical evaluations.
The DEA plans to issue one or more final rules based on the two February proposed rules before November 11, 2023, possibly extending certain telemedicine flexibilities on a permanent basis. In the absence of final rules, the DEA will need to present a different approach to prescribing controlled substances via telemedicine through a new rulemaking process.

MA Plan Requirements Post-PHE: Ensuring a Smooth Transition
ARTICLE / CLIENT ALERT
MA Plan Requirements Post-PHE: Ensuring a Smooth Transition
May 9, 2023
Read time: 11 min
The end of the COVID-19 Public Health Emergency (PHE) on May 11, 2023, presents both regulatory and business risks for Medicare Advantage (MA) plans as some (but not all) emergency declarations and regulatory flexibilities also come to an end. This article summarizes the major MA requirements and flexibilities related to the COVID-19 pandemic and addresses whether they will end along with the PHE. MA plans should monitor the changes to requirements and flexibilities, evaluate the potential impact on beneficiaries, and consider whether operational adjustments or targeted beneficiary communications are appropriate to help mitigate any potential impacts.
The era of the COVID-19 pandemic is approaching its official end. The Biden Administration plans to end the national emergency for COVID-19, declared under Section 201 of the National Emergencies Act, and the public health emergency (PHE) for COVID-19, declared under Section 319 of the Public Health Service Act, on May 11, 2023.
These emergency declarations have been in place since March 2020. They enabled the US Department of Health and Human Services (HHS) and its operating divisions to waive or modify certain requirements for Medicare, Medicaid and the Children’s Health Insurance Program (CHIP). In some instances, HHS linked its exercise of enforcement or programmatic discretion to the declarations. Congress later enacted legislation that imposed new requirements or provided HHS with additional flexibilities tied to the declarations (See generally Families First Coronavirus Response Act; Coronavirus Aid, Relief, and Economic Security Act (CARES); American Rescue Plan Act of 2021; Inflation Reduction Act of 2022; Consolidated Appropriations Act, 2023 (CAA)).
HHS and the Centers for Medicare & Medicaid Services (CMS) implemented new requirements and waived or modified others for the Medicare Advantage (MA) program. For example, MA plans received increased flexibility to waive cost-sharing for COVID-19 treatments and prior authorization for certain services. Most of those changes promise to end with the PHE.
The end of the PHE presents both regulatory and business risks for MA plans. MA plans that overlook the end of the PHE may suddenly find themselves out of compliance with program requirements. At the same time, a return to pre-pandemic requirements may increase plan costs and produce unintended economic and clinical consequences for enrollees.
This article summarizes the major MA requirements and flexibilities related to the COVID-19 pandemic and addresses whether they will end along with the PHE. MA plans should monitor the changes to requirements and flexibilities, evaluate the potential impact on beneficiaries, and consider whether operational adjustments or targeted beneficiary communications are appropriate to help mitigate any potential impacts.
The COVID-19 Determinations and Declarations
In January 2020, Secretary of Health and Human Services Alex M. Azar II determined that the PHE existed. In March 2020, President Trump declared a national emergency under the National Emergencies Act and made an emergency determination under the Stafford Act.
Section 319 of the Public Health Service Act authorizes the Secretary of Health and Human Services to determine that a PHE exists if the Secretary determines that (1) a disease or disorder presents a PHE, or (2) a PHE, including significant outbreaks of infectious diseases or bioterrorist attacks, otherwise exists. The determination lapses in 90 days unless the Secretary renews it.
The determination enables the Secretary to exercise additional legal and regulatory authorities to respond to the PHE. The authorities include Section 1135 of the Social Security Act, which empowers the Secretary to waive statutory and regulatory requirements for Medicare, Medicaid and CHIP. For the COVID-19 pandemic, the Secretary delegated the authority to prescribe the scope of the waiver to the CMS administrator.
The Secretary has renewed the PHE for COVID-19 many times since March 2020. The most recent renewal was in February 2023. The PHE is set to lapse on May 11, 2023.
Key COVID-19 Requirements and Flexibilities for MA Plans
HHS issued its roadmap for the transition from the PHE on February 9, 2023. The roadmap addresses many specific actions and initiatives, such as expanding access to telehealth services, providing support for mental health and substance use disorder treatment, and improving data collection and analysis to better track COVID-19 and other public health threats.
CMS issued a corresponding fact sheet on February 27, 2023. The fact sheet addresses the agency’s approach to COVID-19 flexibilities going forward. On April 27, 2023, CMS issued a list of frequently asked questions regarding the CMS waivers, flexibilities and the end of the PHE addressing all programs, including Medicare, Medicaid, CHIP and private insurance.
The following table summarizes the anticipated dispositions of key flexibilities for MA plans:
|
Flexibility |
Disposition |
|
COVID-19 Vaccines COVID-19 vaccinations are currently covered under Medicare Part B and Part D without cost sharing. MA plans must pay for the vaccine and its administration for beneficiaries enrolled in their plans. Provider payment rates are determined by the contract between the MA plan and the provider when such a contract is in place and may or may not include additional payments for at-home COVID-19 vaccinations. |
Does not expire. The US Food and Drug Administration’s emergency use authorizations for COVID-19 vaccines (and treatments and tests) will remain effective after the PHE ends on May 11, 2023. COVID-19 vaccines will continue to be covered under Part B and Part D. MA beneficiaries will pay nothing for a COVID-19 vaccination if they receive their vaccinations from an in-network provider. |
|
Coverage of Testing and Testing-Related Services for COVID-19 MA plans are not permitted to charge cost sharing for clinical laboratory tests for the detection of COVID-19, the administration of such tests and specified COVID-19 testing-related services. MA plans also may not impose any prior authorization or other utilization management requirements with respect to the coverage of COVID-19 testing and its administration. |
End of PHE People enrolled in MA plans can continue to receive COVID-19 PCR and antigen tests when the test is covered by Medicare, but their cost-sharing may change when the PHE ends. |
|
COVID-19 At-Home Testing MA beneficiaries pay no cost sharing for COVID-19 at-home testing. |
End of PHE MA plans will no longer be required to offer free at-home tests; however, some plans may continue providing them as a supplemental benefit. |
|
COVID-19 Treatment MA beneficiaries pay no cost sharing for certain COVID-19 treatments, including oral antiviral drugs (such as Paxlovid). Part D plans are encouraged to pay dispensing fees for these drugs that may be higher than usual. |
This flexibility will continue following the end of the COVID-19 PHE while the US government-procured product remains available. MA beneficiaries may face cost-sharing requirements for certain COVID-19 pharmaceutical treatments. Part D plans are required to cover oral antiviral treatments not procured by the US government even if they are only available through emergency use authorization until December 31, 2024. CAA, Pub. L. No. 117-328, § 4131 (2022). |
|
Telehealth MA plans have flexibility to waive certain requirements with regard to coverage and cost sharing during the PHE, and expand coverage beyond those telehealth benefits approved by CMS in the plan’s benefit package. |
End of PHE |
|
Special Requirements During a Disaster or Emergency MA plans are required to do the following:
|
Ends 30 days after the latest applicable end date of the PHE, national emergency or state disaster declaration (when multiple declarations apply to the same geographic area). See 42 C.F.R. § 422.100(m). |
|
Extensions to File Appeal: CMS allows MA and Part D plans, as well as the Part C and Part D Independent Review Entities (IREs), to allow extensions to file appeals. Specifically, 42 C.F.R. 422.582(c) and 42 CFR 423.582(c) allow a Part C or Part D plan to extend the timeframe for filing a request if there is good cause for the late filing.
Extensions to Adjudicate: MA plans may extend the timeframe to adjudicate organization determinations and reconsiderations for medical items and services (but not Part B drugs) by up to 14 calendar days if (i) the enrollee requests the extension; (ii) the extension is justified and in the enrollee’s interest due to the need for additional medical evidence from a noncontract provider that may change an MA organization’s decision to deny an item or service; or (iii) the extension is justified due to extraordinary, exigent or other non-routine circumstances and is in the enrollee’s interest.
Process an Appeal with Incomplete Appointment of Representation Forms: MA and Part D plans, as well as the Part C and Part D IREs, are allowed to process an appeal even with incomplete Appointment of Representation forms.
Process Appeals with Incomplete Information: MA and Part D plans, as well as the Part C and Part D IREs, are allowed to process requests for appeal that don’t meet the required elements, but instead use information that is available.
Good Cause: MA and Part D plans, as well as the Part C and Part D IREs, are allowed to utilize all flexibilities available in the appeal process as if good cause requirements are satisfied.
|
End of PHE |
|
Reductions in Cost-Sharing CMS allows Medicare Advantage Organizations (MAOs) to waive or reduce enrollee cost-sharing for beneficiaries enrolled in their MA plans who are impacted by the outbreak where the waiver or reduction in cost-sharing is tied to the COVID-19 outbreak.
|
End of PHE |
|
SNP Model of Care Compliance MAOs may implement strategies that do not fully comply with their approved SNP model of care in order to provide care to enrollees while ensuring that enrollees and healthcare providers are also protected from the spread of COVID-19.
|
End of PHE |
|
Additional or Expanded Benefit Offerings CMS exercised enforcement discretion to allow MA plans to expand telehealth services and other mid-year benefit enhancements (beyond those included in their approved 2020, 2021 and 2022 bids describing covered benefits) when such mid-year benefit enhancements are provided in connection with the COVID-19 outbreak, are beneficial to enrollees and are provided uniformly to all similarly situated enrollees.
|
End of PHE |
|
90-day Supply Part D sponsors must permit enrollees to obtain the total supply prescribed for a covered Part D drug up to a 90-day supply in one fill or refill if requested by the enrollee, if prior authorization or step therapy requirements have been satisfied, and if no safety edits otherwise limit the quantity or days’ supply. CARES Act, Pub. L. No. 116-136, § 3714 (2020).
|
End of PHE |
|
Prior Authorization Part D sponsors may waive prior authorization requirements at any time that they otherwise would apply it to Part D drugs used to treat or prevent COVID-19, if or when such drugs are identified. Part D sponsors can also choose to waive or relax prior authorization requirements at any time for other formulary drugs in order to facilitate access with less burden on beneficiaries, plans and providers. |
End of PHE |
|
“Refill-Too-Soon” Edits and Maximum Day Supply Part D sponsors must relax their “refill-too-soon” edits. Part D sponsors continue to have operational discretion as to how these edits are relaxed, as long as access to Part D drugs is provided at the point of sale. |
End of PHE |
|
Home or Mail Delivery of Part D Drugs Part D sponsors have been permitted to voluntarily relax any plan-imposed policies that may discourage certain methods of delivery, such as mail or home delivery, for retail pharmacies that choose to offer these delivery services in situations when a disaster or emergency makes it difficult for enrollees to get to a retail pharmacy.
|
End of PHE |
|
COVID-19 Oral Antivirals (Dispensing Fees) Part D sponsors are permitted to pay pharmacy claims for dispensing fees of oral antiviral drugs for the treatment of COVID-19 without enrollee cost sharing, and report prescription drug events for the dispensing fee claims.
|
End of PHE |
MA plans should continuously monitor updated guidance from CMS to stay informed about how these changes will impact them and other industry stakeholders.
MA plans should take several additional steps during the transition from the PHE, including the following:
- Assess the impact: Review the waivers and flexibilities allowed during the PHE and assess the impact of their expiration on plan benefits, costs and health outcomes.
- Adjust operations: Consider whether any operational, staffing or system changes are necessary for a smooth transition. Implement changes as appropriate.
- Communicate with members: Promptly inform members about any changes in benefits, costs or operations that may impact them. Note how the changes may affect the options available to members in the future.
- Communicate with providers: Promptly inform providers about any changes that may impact their ability to continue providing care to members.
By taking these steps, MA plans can help ensure a smooth transition for all stakeholders.

Global Legal Insights: Cartels 2023 | Belgium
ARTICLE
Global Legal Insights: Cartels 2023 | Belgium
May 2023
Read time: 2 min
The GLI Cartels 2023 covers key topics including law & enforcement, investigative powers, cartel enforcement activity, decision making procedures, leniency / amnesty, settlement of cases, third party complaints, sanctions and cross-border issues.
Hendrik Viaene has contributed an extensive chapter relating to the law in Belgium.
To read the Belgium chapter, please click here.
To access the full Guide, please click here.
